Laboratory diagnostics of COVID-19
Authors:
I. Lochman 1; J. Kratochvíla 2; B. Friedecký 2
Authors‘ workplace:
Laboratoř klinické imunologie a sérologie, Spadia Lab. a Katedra biomedicínských oborů Lékařské fakulty Ostravské university, Ostrava
1; SEKK Pardubice
2
Published in:
Klin. Biochem. Metab., 28, 2020, No. 3, p. 93-96
Overview
Pandemic caused by SARS-CoV-2 virus is accompanied by a wealth of information that also deals with the laboratory diagnosis of the disease caused by the virus, which has been named COVID-19. The aim of this communication is to contribute to the issue of how to indicate and interpret the results of laboratory tests performed in the diagnosis of COVID-19.
Keywords:
SARS-CoV-2 – COVID-19 – laboratory diagnostics.
Sources
1. Trojánek, M., Grebenyuk, V., Herrmannová, K., Nečas, T., Gregorová, J., et al. A novel coronavirus (SARS-CoV-2) and COVID-19. Čas. Lék. čes. 2020, 159, p. 55–66.
2. Friedecký, B., Kratochvíla, J. Laboratorní aspekty COVID-19. Diagnostika, epidemiologie, prognóza pacientů. Klin. Biochem. Metab., 2020, 3, 97-105.
3. Lochman, I. Laboratorní diagnostika COVID-19. Alergie, 2020, 22(3): p. 200-202.
4. Pütz G, Müller M, Winkler K.: A cohort-based emergency plan to maintain functionality in a clinical laboratory during the 2020 COVID-19 epidemic outbreak. J Lab Med 2020, 44/3:113-115.
5. Vabret, N., Britton, G. J., Gruber, C., et al. Immuno-logy of COVID-19: Current State of the Science. Immunity, 2020, 52, p. 910 – 941.
6. Grasis, J. A. The Intra-Dependence of Viruses and the Holobiont. Frontiers in Immunology, 2017, 8, Article ID 1501.
7. Baedke, J., Fábregas-Tejeda, A., Delgado, A. N. The holobiont concept before Margulis. J Exp. Zool. (Mol. Dev. Evol.), 2020, 334, p. 149–155.
8. Postler, T. S., Ghosh, S. Understanding the Holo-biont: How microbial metabolites affect human health and shape the immune system. Cell Metab., 2017, 26(1), p. 110–130.
9. Pathak, A., Agrawal, A. Evolution of C-Reactive Protein. Frontiers in Immunology, 2019, 10, Article ID 943.
10. Elvington, M., Liszewski, K. M., Atkinson, J. P. Evolution of the complement system: from defense of the single cell to guardian of the intravascular space. Immunol. Rev., 2016, 274(1), p. 9 – 15.
11. Robson, B. COVID-19 Coronavirus Spike Protein Analysis for Synthetic Vaccines, a Peptidomimetic Antagonist, and Therapeutic Drugs, and Analysis of a Proposed Achilles’ Heel Conserved Region to Minimize Probabi-lity of Escape Mutations and Drug Resistance. Comput. Biol. Med., 2020, Apr 11, 103749. doi: 10.1016/j.compbiomed.2020.103749.
12. Roussel Y, Giraud-Gatineau A, Jimeno MT, Rolain J-M, Zandotti C, et al. SARS-CoV-2: fear versus data. Int J Antimicrob Agents 2020 Mar 19: 105947, doi: 10.1016/j.ijantimicag.2020.105947.
13. Bernstein, K. E., Khan, Z., Giani, J. F., Cao, D. Y., Bernstein, E. A., Shen, X. Z. Angiotensin-conver-ting enzyme in innate and adaptive immunity. Nat. Rev. Nephrol., 2018, 14(5), p. 325–336.
14. Human Coronavirus Types. CDC page: https://www.cdc.gov/coronavirus/types.html.
15. Kikkert, M. Innate Immune Evasion by Human Respiratory RNA Viruses. J Innate Immun., 2020, 12, p. 4–20.
16. Walls, A. C., Park, Y.-J., Tolorici, M. A., Wall, A., McGuire, A. T., Veesler, D. Structure, Function, and Antigenicity of the SARS-CpB-2 Spike Glycoprotein. Cell, 2020, 180, p. 1-12.
17. Zhang, H., Penninger, H. M., Li, Y., Zhong, N., Slutsky, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Car. Med., 2020, 46, p. 586 – 90.
18. Xu, H., Zhong, L., Deng, J., et al. High expression of ACE2 receptor of 2019-nCov on the epithelial cells of oral mucosa. Int. J Oral Sci., 2020, 12, Article ID 8.
19. Jonsdottir, H. R. and Dijkman, R. Coronaviruses and the human airway:a universal system for virus-host interaction studies. Virol. J., 2016, 13, p. 24. doi: 10.1186/s12985-016-0479-5.
20. Jiang, S., Hillyer, C., Du, L. Neutralizing antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends in Immunology, 2020, 41(5), p. 355-9.
21. Subbarao, K., Mahanty, S. Respiratory virus infections: Understanding COVID-19. Immunity, 2020, doi: https://doi.org/10.1016/j.immuni.2020.05.004.
22. Töpfer, E., Boraschi, D., Italiani, P. Innate Immune Memory: The Latest Frontier of Adjuvanticity. J. Immunol. Res., 2015, Vol. 2015, Article ID 478408, 7 pages http://dx.doi.org/10.1155/2015/478408.
23. Netea, M. G., Quintin, J., van der Meer, J. W. M. Trained Immunity: A Memory for Innate Host Defense. Cell Host & Microbe, 2011, 9, p. 355-61.
24. Netea, M. G., Joosten, L. A. B., Latz, E., et al. Trained immunity: a program of innate immune memory in health and disease. Science, 2016, April 22, 352(6284), aaf1098. doi:10.1126/science.aaf1098.
25. Goetz L, Yang J, Greene W, Zhu Y.: A COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies. J Appl Lab Med 2020, https://doi.org/10.1093/jalm/jfaa137.
26. Zhou, G., Zhao, Q. Perspectives on Therapeutic Neutralizing Antibodies Against the Novel Coronavirus SARS-CoV-2. Int. J Biol. Sci., 2020, 16(10), p. 1718-1723.
27. Crawford, K. H. D., Eguia, R., Dingens, A. S., et al. Protocol and Reagents for Pseudotyping Lentiviral Particles With SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses, 2020,12(5), E513. doi: 10.3390/v12050513.
28. Seydoux, E., Homad, L. J., MacCamy, A. J., et al. Analysis of a SARS-CoV-2 infected individual reveals development of potent neutralizing antibodies to distinct epitopes with limited somatic mutation, Immunity, 2020, doi: https://doi.org/10.1016/ j.immuni.2020.06.001.
29. Chen, C., Wang, H., Liang, Z., et al. Predicting Illness Severity and Short-Term Outcomes of COVID-19: A Retrospective Cohort Study in China. The Innovation, 2020, doi: 10.1016/j.xinn.2020.04.007. http://www.cell.com/the-innovation.
30. Bohn, M. K., Lippi, G., Horvath, A., et al. Molecular, Serological, and Biochemical Diagnosis and Monitoring of COVID-19: IFCC Taskforce Evaluation of the Latest Evidence. Clin. Chem. Lab. Med., 2020, May 27, doi: 10.1515/cclm-2020-0722.
31. Okba, N. M. A., Muller, M. A., Li, W., et al. SARS-Cov-2 specific antibody responses in COVID-19 patients. medRxiv preprint doi: http://doi.org/10.1101/2020.03.18.20038059.
32. Zhang, W., Du, R.-H., Li, B., et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerging Microbes & Infections, 2020, 9(1), p. 386-389.
33. Lv, D. F., Ying, Q. M., Weng, Y. S., et al. Dynamic change process of target genes by RT-PCR testing of SARS-Cov-2 during the course of a Coronavirus Disease 2019 patient. Clin. Chim. Acta, 2020, 506, p. 172-5.
Labels
Clinical biochemistry Nuclear medicine Nutritive therapistArticle was published in
Clinical Biochemistry and Metabolism
2020 Issue 3
Most read in this issue
- Laboratory diagnostics of COVID-19
- Vitamin D – prevention and treatment in children and adolescents
- Vitamin D 2019 - standardization and chaos. Miniature model of the presentation of laboratory science at present.
- Vitamin D and cardiovascular disease. What do we know about this in 2020?